2023
Biomarker analysis to predict response in patients with metastatic mismatch repair proficient colorectal cancer treated with regorafenib and nivolumab.
Miao R, Kim D, Yu J, Kovari B, Mehta R, Strosberg J, Imanirad I, Iyer S, Uhlik M, Benjamin L, Kim R. Biomarker analysis to predict response in patients with metastatic mismatch repair proficient colorectal cancer treated with regorafenib and nivolumab. Journal Of Clinical Oncology 2023, 41: 228-228. DOI: 10.1200/jco.2023.41.4_suppl.228.Peer-Reviewed Original ResearchProgression free survivalMedian progression free survivalTreated with regorafenibOverall survivalPD-L1Tumor microenvironmentColorectal cancerMedian OSCD8 expressionPartial responseTreg cellsImmune desertPredictive biomarkersAssociated with prolonged progression free survivalMismatch repair-proficient colorectal cancersProlonged progression free survivalDisease control ratePhase I/Ib studyPredicting clinical benefitPD-L1 expressionPretreatment tumor samplesPotential predictive biomarkersPMMR colorectal cancerBiomarker-positiveBiomarker-negative patients
2020
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial
Goldberg SB, Schalper KA, Gettinger SN, Mahajan A, Herbst RS, Chiang AC, Lilenbaum R, Wilson FH, Omay SB, Yu JB, Jilaveanu L, Tran T, Pavlik K, Rowen E, Gerrish H, Komlo A, Gupta R, Wyatt H, Ribeiro M, Kluger Y, Zhou G, Wei W, Chiang VL, Kluger HM. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. The Lancet Oncology 2020, 21: 655-663. PMID: 32251621, PMCID: PMC7380514, DOI: 10.1016/s1470-2045(20)30111-x.Peer-Reviewed Original ResearchConceptsBrain metastasis responseYale Cancer CenterPD-L1 expressionPhase 2 trialUntreated brain metastasesBrain metastasesAdrenal insufficiencyAdverse eventsMetastasis responseCNS diseaseCancer CenterCohort 2Cohort 1Eastern Cooperative Oncology Group performance statusTreatment-related serious adverse eventsModified Response Evaluation CriteriaStage IV NSCLCTreatment-related deathsAcute kidney injuryPD-1 blockadeSerious adverse eventsSolid Tumors criteriaPhase 2 studyProportion of patientsResponse Evaluation Criteria